Levoglucosenone: Bio-Based Platform for Drug Discovery

Jason E. Camp1* and Ben W. Greatrex2
1Circa Sustainable Chemicals, York, United Kingdom, 2School of Science and Technology, University of New England, Armidale, NSW, Australia

Levoglucosenone (LGO) is a bio-privileged molecule that can be produced on scale from waste biomass. This chiral building block has been converted via well-established chemical processes into previously difficult-to-synthesize building blocks such as enantiopure butenolides, dihydropyrans, substituted cyclopropanes, deoxy-sugars and ribonolactones. LGO is an excellent starting material for the synthesis of biologically active compounds, including those which have anti-cancer, anti-microbial or anti-inflammatory activity. This review will cover the conversion of LGO to biologically active compounds as well as provide future research directions related to this platform molecule.

Keywords: levoglucosenone, bio-mass, platform chemical, chiral building block, drug discovery

INTRODUCTION

Levoglucosenone (LGO, 1) is a chiral building block that is readily available from the pyrolysis of materials containing cellulose, including biomass waste such as wood chips and bagasse. Over the past 50 years, research into the chemistry of LGO has established the high degree of orthogonality in the reactive functional groups, and demonstrated the excellent stereochemical control offered by the bicyclic ring-system (Witczak and Tatsuta, 2002; Witczak, 2007; Sarotti et al., 2012a; Comba et al., 2018; Kühlborn et al., 2020). The chirality at C1 and C5 in LGO gives it advantages in stereoselective synthesis compared to achiral biomass derivatives such as furfural, while the reduced number of chiral centers simplifies its use compared to monosaccharides. Enantio-, stereo-, regio- and chemoselective reactions have been executed around the core ring-system. These include, 1,6-anhydro ring opening (Shafigzadeh et al., 1979; Tagirov et al., 2015; Comba et al., 2016; Pedersen and Pedersen, 2021), Baeyer-Villiger oxidation (Koseki et al., 1990; Koseki et al., 1991; Teixeira et al., 2016; Bonneau et al., 2018; Diet-Neant et al., 2018), 1,2-addition (Shafigzadeh and Chin, 1977; Tsypysheva et al., 2000; Giordano et al., 2012; Debsharma et al., 2019; Sharipov et al., 2019), α-substitution (Ward and Shafigzadeh, 1981; Ledingham E. et al., 2017; Ledingham E. T. et al., 2017; Giri et al., 2017; Hughes et al., 2018; Liu et al., 2020), cycloaddition/cyclization (Yatsynich et al., 2003; Novikov et al., 2009; Faizullina et al., 2011; Samet et al., 2011; Sarotti et al., 2012b; Banwell et al., 2020; Fadlallah et al., 2020; Liu et al., 2020), and conjugate addition reactions (Shafigzadeh et al., 1982; Essig, 1986; Samet et al., 1996; Trahanovsky et al., 2003) (Figure 1). These reactions have led to the controlled synthesis of a multitude of important biologically active motifs, including enantiopure butenolides, dihydropyrans, substituted cyclopropanes, deoxy-sugars and ribonolactones. The reactivity of the ketone and enone functionalities is influenced by the 1,6-anhydro bridge, which strongly biases reaction to occur from the less hindered exo-face of the molecule. Whilst the reactivity and potential of this molecule is well understood, it is only recently that it has been produced on industrial scale allowing its use as a chiral feedstock (Lawrence et al., 2012). This review will focus on the use of LGO as a starting material used for the synthesis of biologically active materials, specifically: known bioactive compounds, analogues of bioactives.
where the intact LGO ring-system has been incorporated into the final structure as a bioisostere, and novel materials. In addition, this review will briefly highlight how LGO derivatives can intercept routes to drugs currently in production.

Synthesis of Known Biologically Active Molecules

Enantiopure cyclopropanes are found in a variety of existing biologically active molecules, and are favoured for their rigidity and relative stability under biological conditions. There are a number of approaches for the preparation of cyclopropanes from LGO including the direct cyclopropanation of the alkene of either LGO or one of its derivatives (Samet et al., 2007; Ledingham E. et al., 2017), reactions of malonates with the 3-iododerivative of LGO (Valeev et al., 1999), or by transformation of LGO into a suitably reactive species for cyclization. Using this last approach, Stockton and Greatrex (2016) converted LGO into substituted butyrolactones via either 1) reductive cross-coupling and Baeyer-Villiger oxidation, or 2) reduction then Baeyer-Villiger oxidation (Figure 2). Lactone 2 and 6 were then converted to epoxides 3 and 7 using standard protocols. Finally, treatment of the epoxyesters 3 or 7 with lithium hexamethyldisilazide (LiHMDS) in tetrahydrofuran (THF) gave cyclopropanes 4 and 8, which following elaboration of functional groups led to an intermediate used for the synthesis of the selective glutamate receptor antagonist PCCG-4 and GABA<sub>C</sub> receptor agonist (1S, 2S)-TAMP, respectively.

Tetrodotoxin is the principal toxin of the pufferfish that acts through specific inhibition of sodium ion influx through excitable membranes. In a series of publications, Isobe and co-workers reported the first enantioselective total synthesis of this potent biologically active compound using LGO as a key building block (Figure 3) (Bamba et al., 1996; Urabe et al., 2006; Nishikawa and Isobe, 2013). This example demonstrates the utility and reaction control possible using LGO, whereby a one-pot two step C3 bromination of LGO followed by Diels–Alder cycloaddition afforded tricycle 9 as a single regio- and diastereomeric isomer. This transformation set key stereocenters that were then relayed into the final natural product tetrodotoxin via key intermediate 10.

Oncolys Bipharma used the reaction of LGO with TMS-acetylide to give alkyne-alcohol 11 as a result of selective 1,2-addition of the nucleophile to the ketone (Figure 4) (Nagai et al., 2015). The bicyclic alcohol 11 was then converted to 4′-ethynyl D4T (censavudine), which is a stavudine analogue with decreased cytotoxicity. This route via LGO allowed for the synthesis of the active substance in a simpler way, at lower cost and in larger quantities than previous routes. Censavudine has been investigated as a novel drug therapy for human immunodeficiency (HIV), with greater activity against the less common HIV-2 variant (Smith et al., 2015).

Levoglucosenone in Analogue Synthesis or as a Bioisostere

In addition to the synthesis of known biologically active compounds, LGO has been used extensively in the synthesis of analogues of bioactives. For example, many substituted napthoquinone compounds are known to have antibiotic activity, such as the natural product eleutherin isolated from Eleutherine bulbosa (Bianchi and Ceriotti, 1975). LGO has been used for the synthesis of a series of quinone derivatives, with the core of the LGO converted into a tetrahydropyran or...
dihydropyranone ring. Freskos and Swenton (1985) performed a cycloaddition reaction between LGO and benzofuranone 12 to afford tetracycle 13 in moderate yield (Figure 5). Opening of the acetal ring and deoxygenation afforded napthohydroquinone derivative 14 as a single enantiomer, while a later report from the same group gave the natural product hongkonin (Swenton et al., 1996). Chew et al. (1988) subjected LGO and dibromoxylene 15 to sonication to afford tetracycle 16 as a single enantiomer (Figure 5). Functional group modification gave pyranonaphthoquinone derivative 17.

Conjugate addition to the enone functionality of LGO has also been used to synthesize biologically active derivatives of known compounds. Thromboxanes play a major role in blood clot formation (thrombosis) and are formed via the oxidation of arachidonic acid in vivo. Tolstikov and Tolstikov (2007) employed the LGO ring-system as a bioisostere for the cyclohexyl group was examined by Eiden et al. (1994) in their study of materials that bind to the N-methyl-d-aspartate receptor NMDA receptor complex (Figure 7). Starting with LGO, reduction and then Strecker reaction afforded the aminonitrile 21. Reactions of the aminonitrile 21 with aryl Grignard reagents gave a series of CNS-active arylamines including 22, which was shown to possess low micromolar activity at the NMDA receptor.

**Synthesis of Novel Bioactive Materials**

Due to the highly functionalized and rigid nature of LGO, as well as its well understood reactivity, it has been used extensively as a building block for the synthesis of novel biologically active compounds. 1,2-Addition to the carbonyl of LGO was used by Czubatka-Bienkowska et al. (2017) for the preparation of S-glycosylated thiosemicarbazone derivatives, a class of molecules that have shown potential medical applications as antiviral, antibacterial and anticancer drugs. Thus, condensation of the thiosemicarbazide with LGO in acetic acid afforded the desired adduct 23 in good yield (Figure 8). Subsequent conjugate addition of the 1-thioglucose derivative to thiosemicarbazone 23 gave S-glycosylated thiosemicarbazone 24. Testing of the compound library for in vitro anticancer activity...
showed significant activity against A2780 cancer cell line via induction of DNA damage, though this effect is not associated with apoptosis or oxidative stress induction.

The 1,4-addition of thiols to LGO has been used extensively for the synthesis of biologically active levoglucosenone derivatives. Giri et al. (2016) used the reaction of 1-hexanethiol with LGO in the presence of a base to afford adduct 25 in good yield (Figure 9). The series of thio-derivatives synthesized in this way showed activity against hepatocarcinoma cell lines and also illuminated the key role of the carbonyl functionality to exert biological activity. Similarly, Witczak et al. (2014) demonstrated that substituted thiophenols could be efficiently added to LGO in the presence of triethylamine to give thio-acid 26 (Figure 9). In the same report, 1-thiosugars were shown to be competent nucleophiles for conjugate addition into LGO. For example, addition of protected 1-thioglucose 27 to LGO in the presence of triethylamine afforded the desired adduct 28.
in good yield (Figure 9). Importantly, this series of functional CARB-pharmacophores demonstrated cytotoxicity and apoptosis against human cancel cell lines (A549, LoVo, MCF-7 and HeLa). The thio-sugar motif was shown to be a promising construct for the development of novel antineoplastic drugs.

Nitrogen and oxygen nucleophiles have also been shown to undergo conjugate addition to LGO and a number of biologically active derivatives have been formed using this chemistry. For example, Westman et al. (2007) have patented the synthesis of LGO derivatives for the treatment of disorders such as cancer, autoimmune diseases and heart diseases (Figure 10). The reaction of LGO with triazole derivative 29 in the presence of base afford the desired 1,4-addition adduct 30 as a single enantiomer. The approximately 90 derivatives were tested in a range of assays, including in human H1299 lung carcinoma cells lacking p53 expression and in H1299 His175 cells that carry tetracycline-regulated mutant p53 constructs. From these studies, a group of LGO derivatives were identified including 31 that showed promise in the treatment of disorders in which a malfunctioning p53 pathway could be involved. In a similar synthetic approach, Sarotti and co-workers used the reaction of sodium azide in acetic acid with LGO in the presence of triethylamine to give β-azidoketone 32 (Figure 10) (Tsai et al., 2018). A subsequent click reaction with phenyl acetylene performed without isolation of the β-azidoketone 32 afforded triazole 33. Application of the methodology to a diverse series of acetylenes gave triazole products, which showed satisfactory antitumor activity when evaluated against TNBC cancer cell lines. Primary amines have also been shown to be good nucleophiles for addition to the enone functionality of LGO. For example, further work by Sarotti and co-workers showed that the reaction of propargyl amine to LGO in the presence of base gave addition adduct 34 (Figure 10) (Tsai et al., 2020). Testing of this chain extended series on MDA-MB-231 cells, specifically endogenous mutant p53 knock down (R280K), and by reintroducing p53 R280K in cells lacking p53 expression, anti-proliferative activities against lung and colon cancer cell lines were demonstrated. Further examples of LGO derivatives with anticancer activity have been reported by the same group (Delbart et al., 2022).

Carbon-Carbon bond formation via metal-mediated cross-couplings has also been used for the production of novel biologically active molecules based on LGO. Banwell and co-workers employed a palladium-catalyzed Ullmann cross-coupling between the C3 iodo derivative of LGO 35 and a variety of bromonitropyridines such as 36 affording a range of LGO derivatives (Figure 11) (Liu et al., 2020). It was found that the α-
pyridinylated derivatives of type 37 had potent and selective antimicrobial and/or cytotoxic properties, whereas the azaindole derivatives were essentially inactive in all of the tests conducted.

1,3-Dipolar cycloadditions of nitrones with LGO have also been used for the synthesis of biologically active derivatives. The selectivity of the process was controlled by the 1,6-anhydro bridge and the polarization of the conjugated alkene. Pratesi et al. (2020) exploited the reactivity of the enone functionality of LGO in a dipolar cycloaddition reaction to give derivative 39 via reaction of LGO with nitrone 38 (Figure 12). One of the glycomimetics
showed strong inhibition of the central nervous system expressed hCA VIII as well as selectivity towards a specific isozyme, while inhibitory activity against tumor associated hCA IX (K_i = 35.9 nM) was shown by another of the LGO derivatives. A similar strategy was employed by Peri and co-workers for the construction of Ras activation inhibitors (Müller et al., 2009).

Thus, the reaction of LGO with a series of aromatic nitrones 40 in the presence of zinc(II) chloride afforded the desired levoglucosenone fused isoxazolidines 41a and 41b as a mixture of diastereomers (Figure 12). These scaffolds were then further manipulated to give a total of nine functionalized derivatives and their biological activity examined. These molecules were shown to be a novel set of Ras inhibitors with interesting biological activity both in vitro and towards cells against a representative set of human cancer cell lines.

Using LGO to Intercept Existing Routes to Pharmaceuticals

LGO and its derivatives are attractive building block for the synthesis of key intermediates used in the production of pharmaceuticals, largely due to its well-understood chemistry and availability on scale. As an example, Allais and his team at AgroParisTech have developed straight forward protocols for the facile conversion of LGO to 5-O-benzyl-D-(+)-ribo-1,4-lactone 43, which is a key building block for the synthesis of the COVID-19 anti-infective drug remdesivir (Figure 13) (Flourat et al., 2015; Moreau et al., 2019). In this work, Baeyer-Villiger oxidation of LGO to the butenolide 42 followed by alcohol protection and syn-dihydroxylation gave the protected ribonolactone 43 in good yield and selectivity.

The ready transformation of LGO or its derivatives to 5-hydroxymethylbutyrolactones via the Baeyer-Villiger reaction can be used to access a variety of pharmaceuticals. For example, a hydrogenation-aldol condensation-hydrogenation sequence starting with LGO afforded ketone 44, which was then hydrogenated and oxidized using peracetic acid to give the benzylated butyrolactone 45 (Figure 14) (Ledingham E. T. et al., 2017). The configuration of the benzyl group in the intermediate ketone 44 was controlled by steric interactions with the oxymethylene bridge, resulting in the requisite anti-configuration of substituents in the final butyrolactone. The original route to 45, which was used to construct the core section of the HIV protease inhibitor indinavir reported by Dorsey et al. (1994) was prepared in 5-steps from glutamic acid. This synthesis involved protection/deprotections steps, and strong base, while the more atom-economic synthesis of 45 starting with LGO proceeds in four-high yielding steps in 57% overall yield. This same benzylated butyrolactone has been used for the preparation of vasoactive intestinal peptide inhibitors, and drugs for Alzheimer’s disease.

CONCLUSION

This brief outline has identified a diverse set of bioactive materials that can be prepared from LGO, and include materials that retain the chiral bicyclic structure, or transfer the chirality to new motifs. The orthogonal reactive groups, and the diastereoselectivity imparted by the bicyclic ring-system gives unique opportunities to prepare bioactive compounds. The trend towards using single enantiomer drugs in place of racemates places LGO in a unique position among renewable chemicals. LGO is one of the few chiral pyrolysis products obtained from cellulose, and is the principle product in bio oils formed from the acid-catalysed pyrolysis of cellulose. This sets it apart from other platform chemicals such as furfural, itaconic acid, and chloromethyl furfural which have lost the chirality present in the carbohydrate precursor, and require asymmetric strategies for their use in chiral bioactive synthesis. The development of reactions for the LGO ring-system coupled with its availability on large scale will provide additional opportunities to access known and new bioactive chemicals.

AUTHOR CONTRIBUTIONS

JC and BG both contributed to the writing of this review.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fchem.2022.902239/full#supplementary-material

REFERENCES

Bamba, M., Nishikawa, T., and Isobe, M. (1996). Tin-assisted Cyclization for Chiral Cyclohexane Synthesis, an Alternative Route to (−)-tetrodotoxin Skeleton. Tetrahedron Lett. 37 (45), 8199–8202. doi:10.1016/0040-4039(96)01860-6
Banwell, M. G., Liu, X., Connal, L. A., and Gardiner, M. G. (2020). Synthesis of Functionally and Stereochromically Diverse Polymers via Ring-Opening Metathesis Polymerization of Derivatives of the Biomass-Derived Platform Molecule Levoglucosenone Produced at Industrial Scale. Macromolecules 53 (13), 5308–5314. doi:10.1021/acs.macromol.0c01305
Bianchi, C., and Ceriotti, G. (1975). Chemical and Pharmacological Investigations of Constituents of Eleutherine Bulbosa (Müller) Urb. (Iridaceae). J. Pharm. Sci. 64 (8), 1305–1308. doi:10.1002/jps.2600640809
Bonneau, G., Peru, A. A. M., Flourat, A. L., and Allais, F. (2018). Organic Solvent- and Catalyst-free Baeyer–Villiger Oxidation of Levoglucosenone and Dihydrolevoglucosenone (Cyrene): a Sustainable Route to (S)-γ-hydroxymethyl-α,β-butenolide and (S)-γ-hydroxymethyl-γ-butylactone. Green Chem. 20 (11), 2455–2458. doi:10.1039/c8gc00553b
Chew, S., Ferrier, R. J., and Sinnwell, V. (1988). An Approach to the Pyranonaphthoquinones. Carbohydr. Res. 174, 161–168. doi:10.1016/0008-6215(88)85089-4
Comba, M. B., Suárez, A. G., Sarotti, A. M., Mangione, M. I., Spanevello, R. A., and Giordano, E. D. V. (2016). Synthesis of a 3-Thiomannoside. Org. Lett. 18 (8), 1748–1751. doi:10.1021/acs.orglett.6b0428
Comba, M. B., Tsai, Y.-h., Sarotti, A. M., Mangione, M. I., Suárez, A. G., and Spanevello, R. A. (2018). Levoglucosenone and its New Applications: Valorization of Cellulose Residues. Eur. J. Org. Chem. 2018 (5), 590–604. doi:10.1002/ejoc.201701227
Czubak-Bienkowska, A., Sarnik, J., Macieja, A., Galita, G., Witczak, Z. J., and Poplawski, T. (2017). Thio-functionalized Carbohydrate Thiosemicarbazones and Evaluation of Their Anticancer Activity. Bioorg. Med. Chem. Lett. 27 (12), 2713–2720. doi:10.1016/j.bmcl.2017.04.051
Debsharma, T., Behrendt, F. N., Laschewsky, A., and Schlaad, H. (2019). Ring-Opening Metathesis Polymerization of Biomass-Derived Levoglucosenol. *Angew. Chem. Int. Ed.* 58 (20), 6718–6721. doi:10.1002/anie.201814501

Delbart, D. I., Giri, G. F., Cammarata, A., Pan, M. D., Bareño, L. A., Amigo, N. L., et al. (2022). Antineoplastic Activity of Products Derived from Cellulose-Containing Materials: Levoglucosenone and Structurally-Related Derivatives as New Alternatives for Breast Cancer Treatment. *Invest. New Drugs* 40, 30–41. doi:10.1007/s10637-021-11167-6

Diot-Néant, F., Rastoder, E., Miller, S. A., and Allais, F. (2018). Chemo-enzymatic Synthesis and Free Radical Polymerization of Renewable Acrylate Monomers from Cellulose-Based Lactones. *ACS Sustain. Chem. Eng.* 6 (12), 17284–17293. doi:10.1021/acssuschemeng.8b04707

Dorsey, B. D., Levin, R. B., McDaniel, S. L., Vacca, J. P., Guare, J. P., Darke, P. L., et al. (1994). L-735,524: the Design of a Potent and Orally Bioavailable HIV Protease Inhibitor. *J. Med. Chem.* 37 (21), 3443–3451. doi:10.1021/jm00474a001

Eiden, F., Denk, F., and Höfner, G. (1994). ZNS-wirksame Pyran: Amin- und arylsubstituierte Dioxacyclooctane. *Arch. Pharm. Pharm. Med. Chem.* 327 (7), 405–412. doi:10.1002/ardp.19943270702

Essig, M. G. (1986). Michael Additions of Thiols to Levoglucosenone. *Carbohydr. Res.* 135, 225–231. doi:10.1016/0008-6215(86)90115-0

Fadollahi, S., Peru, A. A. M., Flourat, A. L., and Allais, F. (2020). A Straightforward Access to Functionalizable Polymers through Ring-Opening Metathesis Polymerization of Levoglucosenone-Derived Monomers. *Eur. Polym. J.* 138, 109980. doi:10.1016/j.eurpolymj.2020.109980

Faizzullina, L. K., Safarov, M. G., Spirikhin, L. V., Kolosnitsyn, V. S., Kondrova, Y. A., and Valeev, F. A. (2011). Reaction of Nitroalkanes with Levoglucosenone and its α-halogeno- and α-iodo Derivatives. *Ras Aktivators* 20 (19), 4423–4428. doi:10.1002/ardp.201100168

Giordano, E. D. V., Frinchaboy, A., Suárez, A. G., and Spanevello, R. A. (2012). Synthesis of Tri-O-acetyl-d-allal from Levoglucosenone. *J. Org. Chem.* 77 (25), 11538–11539. doi:10.1021/jo301798n

Giri, G. F., Danieli, M., Martelli, R. A., and Spanevello, R. A. (2016). Cytotoxic Effect of Levoglucosenone and Related Derivatives against Human Hepatocarcinoma Cell Lines. *Bioorg. Med. Chem. Lett.* 26 (16), 3955–3957. doi:10.1016/j.bmcl.2016.07.007

Giri, G. F., Viarengo, G., Furlán, R. L. E., Suárez, A. G., García Véscovi, E., and Spanevello, R. A. (2017). Soybean Hulls, an Alternative Source of Bioactive Compounds: Combining Pyrolysis with Bioguided Fractionation. *Industrial Crops Prod.* 105, 113–123. doi:10.1016/j.indcrop.2017.05.005

Hughes, L., McElroy, C. R., Whitwood, A. C., and Hunt, A. J. (2018). Development of Pharmacologically Relevant Bio-Based Intermediates Though Aldol Condensation and Claisen-Schmidt Reactions of Dihydrolevoglucosenone (Cycrene). *Green Chem.* 20 (19), 4423–4427. doi:10.1039/c7gc01227j

Jager Pedersen, M., and Pedersen, C. M. (2021). Reactivity, Selectivity, and Synthesis of 4-(C-α-hydroxymethyl-γ-iodo) Derivatives. Cyclopentaannulation of Levoglucosenone. *Carbohydr. Res.* 4602. doi:10.1002/ardp.19943270702

Lawrence, C. H., Raverty, W. D., and Duncan, A. J. (2012). *Method for Converting Lignocellulosic Materials into Useful Chemicals.* Washington, DC: U.S. Patent Office. U.S. Patent Application US2012111714A1.

Ledingham, E. T., Stockton, K. P., and Greatrex, B. W. (2017b). Ef ficient Synthesis of a Potent and Orally Bioavailable HIV Protease Inhibitor. *J. Med. Chem.* 37 (21), 3443–3451. doi:10.1021/jm00474a001

Ledingham, E. T., Stockton, K. P., and Greatrex, B. W. (2017b). Ef ficient Synthesis of a Potent and Orally Bioavailable HIV Protease Inhibitor. *J. Med. Chem.* 37 (21), 3443–3451. doi:10.1021/jm00474a001

Liu, X., Carr, P., Gardiner, M. G., Banwell, M. G., Elbanna, A. H., Khalil, Z. G., et al. (2020). Levoglucosenone and its Pseudoenantiomer Iso-Levoglucosenone as Scaffolds for Drug Discovery and Development. *ACS Omega* 5 (23), 13926–13939. doi:10.1021/acsomega.0c01331

Moreau, M., Bonneau, G., Peru, A., Brunissen, F., Janvier, M., Haudrechy, A., et al. (2019). High-Yielding Diastereoselective Syn-Di-hydroxylation of Protected HBO: An Access to D-(+)-Ribonucleic acid and 5-O-Protected Analogues. *Eur. J. Org. Chem.* 2019 (7), 1600–1604. doi:10.1002/ejoc.201801780

Samet, A. V., Niyaizymetov, M. E., semenov, V. V., Laikhter, A. L., and Evans, D. H. (1996). Comparative Studies of Cathodally-Promoted and Base-Catalyzed Michael Addition Reactions of Levoglucosenone. *J. Org. Chem.* 61 (25), 8786–8791. doi:10.1021/jo961019g

Samet, A. V., Shetstopalov, A. M., Lutov, D. N., Rodinovskaya, L. A., Shetstopalov, A. A., and semenov, V. V. (2007). Preparation of Chiral Cyclopropanes with a Carbohydrate Fragment from Levoglucosenone. *Tetrahedron Asymmetry* 18 (16), 1986–1989. doi:10.1016/j.tetasy.2007.08.013

Shafizadeh, F., and Chin, P. P. S. (1977). Preparation of 1,6-Anhydro-3,4-Dideoxy-β-D-Glucaro-Hexa-2,3-Enopyranos-2-Ulose (Levoglucosenone) and Some Derivatives Thereof. *Carbohydr. Res.* 58 (1), 79–87. doi:10.1016/s0008-6215(00)83406-0

Shafizadeh, F., Furneaux, R. H., and Stevenson, T. T. (1979). Some Reactions of Levoglucosenone. *Carbohydr. Res.* 71 (1), 169–191. doi:10.1016/0008-6215(79)80069-3

Shafizadeh, F., Ward, D. D., and Pang, D. (1982). Michael-addition Reactions of Levoglucosenone. *Carbohydr. Res.* 102 (1), 217–230. doi:10.1016/0008-6215(82)80064-7

Sharipov, B. T., Davydova, A. N., Ryabova, A. S., Galimzyanova, N. F., and Valeev, F. A. (2019). Synthesis and Fungicidal Activity of Methylsulfonylmethyl Ether
